Article
Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).
PloS one - 23 Feb 2011
Campa Daniele, Hüsing Anika, Stein Angelika, Dostal Lucie, Boeing Heiner, Pischon Tobias, Tjønneland Anne, Roswall Nina, Overvad Kim, Østergaard Jane Nautrup, Rodríguez Laudina, Sala Núria, Sánchez Maria-José, Larrañaga Nerea, Huerta José María, Barricarte Aurelio, Khaw Kay-Tee, Wareham Nicholas, Travis Ruth C, Allen Naomi E, Lagiou Pagona, Trichopoulou Antonia, Trichopoulos Dimitrios, Palli Domenico, Sieri Sabina, Tumino Rosario, Sacerdote Carlotta, van Kranen Henk, Bueno-de-Mesquita H Bas, Hallmans Göran, Johansson Mattias, Romieu Isabelle, Jenab Mazda, Cox David G, Siddiq Afshan, Riboli Elio, Canzian Federico, Kaaks Rudolf
Abstract excerpt
The mTOR (mammalian target of rapamycin) signal transduction pathway integrates various signals, regulating ribosome biogenesis and protein synthesis as a function of available energy and amino acids, and assuring an appropriate coupling of cellular proliferation with increases in cell size. In addition, recent evidence has pointed to an interplay between the mTOR and p53 pathways. We investigated the genetic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.